306 related articles for article (PubMed ID: 30020513)
1. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Neuro Oncol; 2018 Nov; 20(12):1573-1583. PubMed ID: 30020513
[TBL] [Abstract][Full Text] [Related]
2. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
[TBL] [Abstract][Full Text] [Related]
3. Imaging prediction of isocitrate dehydrogenase (IDH) mutation in patients with glioma: a systemic review and meta-analysis.
Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
Eur Radiol; 2019 Feb; 29(2):745-758. PubMed ID: 30003316
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
[TBL] [Abstract][Full Text] [Related]
5. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
7. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
[TBL] [Abstract][Full Text] [Related]
8. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate.
Andronesi OC; Loebel F; Bogner W; Marjańska M; Vander Heiden MG; Iafrate AJ; Dietrich J; Batchelor TT; Gerstner ER; Kaelin WG; Chi AS; Rosen BR; Cahill DP
Clin Cancer Res; 2016 Apr; 22(7):1632-41. PubMed ID: 26534967
[TBL] [Abstract][Full Text] [Related]
9. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y
Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594
[TBL] [Abstract][Full Text] [Related]
10. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T
J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540
[TBL] [Abstract][Full Text] [Related]
11. In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
Tiwari V; Mashimo T; An Z; Vemireddy V; Piccirillo S; Askari P; Hulsey KM; Zhang S; de Graaf RA; Patel TR; Pan E; Mickey BE; Maher EA; Bachoo RM; Choi C
Magn Reson Med; 2020 Sep; 84(3):1152-1160. PubMed ID: 32003035
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
[TBL] [Abstract][Full Text] [Related]
13. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
Cuccarini V; Antelmi L; Pollo B; Paterra R; Calatozzolo C; Nigri A; DiMeco F; Eoli M; Finocchiaro G; Brenna G; Tramacere I; Bruzzone MG; Anghileri E
Neurol Sci; 2020 Feb; 41(2):347-355. PubMed ID: 31650436
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic performance of edited 2HG MR spectroscopy of central glioma in the clinical environment.
Juskanič D; Mištinová JP; Hollý S; Sekerešová M; Koleják K; Pátrovič L
MAGMA; 2022 Feb; 35(1):45-52. PubMed ID: 34985589
[TBL] [Abstract][Full Text] [Related]
15. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
[TBL] [Abstract][Full Text] [Related]
16. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate.
Andronesi OC; Rapalino O; Gerstner E; Chi A; Batchelor TT; Cahill DP; Sorensen AG; Rosen BR
J Clin Invest; 2013 Sep; 123(9):3659-63. PubMed ID: 23999439
[TBL] [Abstract][Full Text] [Related]
17. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
[TBL] [Abstract][Full Text] [Related]
18. A comparative study of short- and long-TE ¹H MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors.
Choi C; Ganji S; Hulsey K; Madan A; Kovacs Z; Dimitrov I; Zhang S; Pichumani K; Mendelsohn D; Mickey B; Malloy C; Bachoo R; Deberardinis R; Maher E
NMR Biomed; 2013 Oct; 26(10):1242-50. PubMed ID: 23592268
[TBL] [Abstract][Full Text] [Related]
19. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients.
Jafari-Khouzani K; Loebel F; Bogner W; Rapalino O; Gonzalez GR; Gerstner E; Chi AS; Batchelor TT; Rosen BR; Unkelbach J; Shih HA; Cahill DP; Andronesi OC
Neuro Oncol; 2016 Nov; 18(11):1569-1578. PubMed ID: 27382115
[TBL] [Abstract][Full Text] [Related]
20. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
Branzoli F; Di Stefano AL; Capelle L; Ottolenghi C; Valabrègue R; Deelchand DK; Bielle F; Villa C; Baussart B; Lehéricy S; Sanson M; Marjanska M
Neuro Oncol; 2018 Jun; 20(7):907-916. PubMed ID: 29126125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
